Trouble on the Horizon for UK-based researchers

Episode Summary

Executive Summary: This episode examines how Brexit has destabilized UK participation in European science, especially Horizon Europe. Through interviews with an architect-researcher, a policy adviser, and a proton therapy scientist, it shows how political uncertainty, funding delays, and loss of leadership opportunities are affecting careers, collaborations, and potentially patient outcomes.

Main Topics: Brexit and the Horizon Europe stalemate (Priority: 5/5): The podcast frames Horizon Europe as the central research funding mechanism now caught in UK-EU political disputes, especially over Northern Ireland. UK association is agreed in principle but delayed, leaving science in limbo. How European collaboration benefits research (Priority: 5/5): Rachel Armstrong and Karen Kirby describe EU projects as uniquely multidisciplinary, networked, and intellectually enriching, enabling work that would be hard to do nationally alone. Career disruption and uncertainty for UK researchers (Priority: 5/5): Researchers explain that Brexit has made it hard to plan, lead projects, or know whether UK participation will be accepted, pushing some scientists to relocate or deprioritize UK partners. Government policy, evidence, and decision-making (Priority: 4/5): Graham Reid explains the House of Lords and government advisory process, emphasizing that this issue is emotionally charged but should be judged on evidence and fiscal realities. Financial trade-offs and the cost of association (Priority: 5/5): Association would require the UK to pay roughly £2 billion a year directly, making Horizon participation compete with other public spending for the first time. Scientific and medical consequences of reduced collaboration (Priority: 4/5): Karen Kirby warns that delays or lack of funding could slow trials, reduce discoveries, and hinder advances in proton therapy that may improve future patient care.

Key Arguments: EU research collaboration is unusually effective because it combines diverse disciplines, countries, and institutional strengths into projects that are difficult to replicate domestically. Brexit has changed UK science from a position of integrated leadership to one of uncertainty, where British researchers may no longer be able to coordinate or lead major European projects. The government’s failure to settle Horizon Europe association leaves large sums of allocated science money unused, which may eventually be reclaimed by the Treasury. A UK-only alternative could be tailored to national priorities and global partnerships, but it would have to be built from scratch and would be costly and slow to establish. In proton therapy, international pooling of scarce cases, equipment, and expertise is essential; Brexit makes this less straightforward and can discourage European partners from working with UK teams. Researchers fear that uncertainty harms not just administration but outcomes: delayed trials, missed discoveries, reduced career progression, and weaker patient benefit in the future. Graham Reid argues that the central issue is no longer whether Horizon is desirable in principle, but whether ministers will choose to pay for association or redirect the funds into a domestic scheme.

Data Points: Brexit referendum result: 52% to 48% - The UK vote to leave the EU in June 2016 was described as very close. Horizon Europe budget: €95.5 billion - The EU research and innovation programme running until 2027. UK association timing: Agreed at end of 2021 - The UK was supposed to become an associate member as part of the UK-EU trade deal. Built environment share of global carbon emissions: 40% - Rachel Armstrong used this figure to explain the climate significance of her research area. UK science association cost: About £2,000 million a year - Graham Reid described the annual cost of associating with Horizon Europe. ERC grant losses: 143 UK-based researchers - Mentioned as losing grants unless they relocated to an EU country. UK research alternative funding size: About £2,000 million a year - The same amount could fund either Horizon association or a domestic collaboration scheme. NHS proton therapy investment: Over £250 million - Used to establish clinical proton therapy capability in Manchester. Proton therapy centre rooms in Manchester: 4 rooms - Three clinical gantries and one research room. Age range highlighted for proton therapy: 0–25/26 years - Used to explain why reducing long-term side effects matters particularly for children and young adults. European proton therapy spending: Something like £2 billion - Karen Kirby described the scale of European investment in proton therapy.

Pivotal Quotes: "The built environment contributes 40% to total global carbon emissions" — Rachel Armstrong: She explains why her multidisciplinary sustainability research depends on large collaborative EU projects. "We're in the worst of all possible positions at the moment, where we're neither in EU programmes, nor are we spending the available money on a domestic alternative." — Professor Graham Reid: He describes the policy limbo caused by the unresolved Horizon Europe decision. "There will be discoveries that aren't made." — Karen Kirby: She warns that lack of funding and collaboration could have long-term effects on medical progress.

Implications: UK science risks losing collaboration, leadership, and funding stability unless Horizon Europe access is resolved. Delays may reduce innovation, weaken careers, and slow clinical advances, while a domestic replacement would take time to build.